Clinical Trials
7 trialsNCT01256359 2024-08-15
DOC-MEK
University of Oxford
Phase 2 Completed
NCT01143402 2017-07-26
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT00936221 2016-03-14
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
AstraZeneca
Phase 2 Completed
NCT00866177 2015-08-11
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00338130 2014-08-13
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
AstraZeneca
Phase 2 Completed
NCT01519427 2014-06-18
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01166126 2014-05-15
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
National Cancer Institute (NCI)
Phase 2 Terminated